Bohan Jin

This inventor holds 19 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Alumis Inc., Takeda Pharmaceutical Company Limited, Fronthera U.S. Pharmaceuticals LLC. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bohan Jin. Retrieved from https://idiyas.com/inventor/bohan-jin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 14)

% Patents Active = 57.9

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 7 (Patent Applications = 20)

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 54(Granted Patents)

Location History:

San Diego, CA (US) (2012 - 2024)
San Francisco, CA (US) (2023 - 2024)

Company Filing History:

Takeda Pharmaceutical Company Limited

patents

2 out of 2

Fronthera U.S. Pharmaceuticals LLC

patents

4. 2 out of 8

Sichuan Haisco Pharmaceutical Co., Ltd.

patents

5. 2 out of 2

Xizang Haisco Pharmaceutical Co., Ltd.

patents

6. 1 out of 1

C2 Pharmaceuticals, LLC

patent

7. 1 out of 1

Esker Therapeutics, Inc.

patent

8. 2 out of 834,601

Other

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

TYK2 Inhibitors

Thyroid Hormone Receptor Agonists

Cancer Treatments

Autotaxin Inhibitors

Apoptosis Signal-Regulating Kinase

Hemoglobin Modifiers

1,2,4-Triazoles

Pyridazines

Pyridines

Oxazinopteridines

Hexahydrooxazinopterine

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679850 - TYK2 inhibitors and uses thereof (2026-07-14),

2. 12358899 - Thyroid hormone receptor agonists and uses thereof (2025-07-15),

3. 12351572 - Substituted 1,2,4-triazoles as TYK2 inhibitors (2025-07-08),

4. 12060343 - Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors (2024-08-13),

5. 12006306 - Substituted pyridazines as TYK2 inhibitors (2024-06-11),

6. 11964964 - Thyroid hormone receptor agonists and uses thereof (2024-04-23),

7. 11731956 - Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors (2023-08-22),

8. 11053219 - Substituted pyridines as TYK2 inhibitors (2021-07-06),

9. 11040972 - Autotaxin inhibitors and uses thereof (2021-06-22),

10. 11034671 - Apoptosis signal-regulating kinase inhibitors and uses thereof (2021-06-15),

11. 10787430 - Hemoglobin modifier compounds and uses thereof (2020-09-29),

12. 10711000 - Autotaxin inhibitors and uses thereof (2020-07-14),

13. 9956208 - Compounds for the treatment of cancer and inflammatory diseases (2018-05-01),

14. 9643966 - Compounds for the treatment of cancer and inflammatory diseases (2017-05-09),

15. 9440977 - Compositions, uses and methods for their preparation (2016-09-13),

Title: Bohan Jin: Pioneering Innovator in Biopharmaceuticals

Introduction

Bohan Jin, based in San Diego, CA, is an accomplished inventor with a remarkable portfolio of 13 patents. With a focus on biopharmaceutical innovations, his work primarily addresses critical health issues through novel therapeutic approaches. His contributions have significantly advanced the fields of endocrinology and immunology.

Latest Patents

Among his recent patents, Bohan Jin has developed methods and compositions for the treatment of conditions associated with thyroid hormone receptor activity. This innovative work outlines the use of thyroid hormone receptor agonists, paving the way for new treatment options for various disorders. Additionally, he has explored substituted pyridines as TYK2 inhibitors—chemicals that have potential applications in treating autoimmune disorders, inflammatory disorders, and other significant health concerns.

Career Highlights

Bohan Jin has been instrumental in the advancement of pharmaceutical research while working with prominent companies such as Takeda Pharmaceutical Company Limited and Sichuan Haisco Pharmaceutical Co., Ltd. His expertise and forward-thinking approach have positioned him as a key figure in the biopharmaceutical industry, contributing to groundbreaking discoveries that enhance patient care.

Collaborations

Throughout his career, Bohan Jin has collaborated with distinguished professionals, including Qing Dong and Gene Hung. These partnerships reflect his commitment to advancing scientific research and developing innovative solutions to complex health challenges.

Conclusion

Bohan Jin's dedication to innovation in biopharmaceuticals is evident through his numerous patents and impactful research contributions. As he continues to push the boundaries of what is possible in medicine, his work holds great promise for improving treatment outcomes for patients worldwide.

Profile summary based on public USPTO records.